Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

Details

Serval ID
serval:BIB_6D797C501FA9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Journal
Transfusion
Author(s)
Ceppi F., Rivers J., Annesley C., Pinto N., Park J.R., Lindgren C., Mgebroff S., Linn N., Delaney M., Gardner R.A.
ISSN
1537-2995 (Electronic)
ISSN-L
0041-1132
Publication state
Published
Issued date
06/2018
Peer-reviewed
Oui
Volume
58
Number
6
Pages
1414-1420
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
The first step in the production of chimeric antigen receptor T cells is the collection of autologous T cells using apheresis technology. The procedure is technically challenging, because patients often have low leukocyte counts and are heavily pretreated with multiple lines of chemotherapy, marrow transplantation, and/or radiotherapy. Here, we report our experience of collecting T lymphocytes for chimeric antigen receptor T-cell manufacturing in pediatric and young adult patients with leukemia, non-Hodgkin lymphoma, or neuroblastoma.
Apheresis procedures were performed on a COBE Spectra machine using the mononuclear cell program, with a collection target of 1 × 10 <sup>9</sup> total mononuclear cells per kilogram. Data were collected regarding preapheresis and postapheresis blood counts, apheresis parameters, products, and adverse events.
Ninety-nine patients (ages 1.3-25.7 years) and 102 apheresis events were available for analysis. Patients underwent apheresis at a variety of absolute lymphocyte cell counts, with a median absolute lymphocyte count of 944 cells/μL (range, 142-6944 cells/μL). Twenty-two patients (21.6%) had absolute lymphocyte counts less than 500 cells/μL. The mononuclear cell target was obtained in 100% of all apheresis harvests, and chimeric antigen receptor T-cell production was possible from the majority of collections (94%). Mononuclear cell collection efficiency was 65.4%, and T-lymphocyte collection efficiency was 83.4%. Ten patients (9.8%) presented with minor adverse events during the 102 apheresis procedures, with one exception of a severe allergy.
Mononuclear cell apheresis for chimeric antigen receptor T-cell therapy is well tolerated and safe, and it is possible to obtain an adequate quantity of CD3+ lymphocytes for chimeric antigen receptor T-cell manufacturing in heavily pretreated patients who have low lymphocyte counts.
Keywords
Adolescent, Adult, Autografts, CD3 Complex/blood, Child, Child, Preschool, Humans, Immunotherapy, Adoptive, Infant, Leukapheresis/methods, Leukemia/therapy, Lymphocyte Count, Neuroblastoma/therapy, Receptors, Antigen, T-Cell/blood, Receptors, Chimeric Antigen/blood, Young Adult
Pubmed
Web of science
Open Access
Yes
Create date
15/03/2018 18:23
Last modification date
20/08/2019 15:27
Usage data